Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Immune-related Adverse Event 1Hematologic Neoplasms 1Cardiovascular Diseases 1

Interventions

Cyclophosphamide 207fludarabine phosphate 182Azacitidine 153fludarabine 141Busulfan 139Tacrolimus 118Mycophenolic Acid 111Cytarabine 110Whole-Body Irradiation 105Peripheral Blood Stem Cell Transplantation 97Antilymphocyte Serum 95Melphalan 89Filgrastim 86Cyclosporine 81Methotrexate 78Decitabine 78venetoclax 63Granulocyte Colony-Stimulating Factor 56Radiotherapy 49Stem Cell Transplantation 48Thiotepa 46Cord Blood Stem Cell Transplantation 43thymoglobulin 41Clofarabine 41Etoposide 35Specimen Handling 34Methylprednisolone 34Sirolimus 33Biopsy 27Injections 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × Antineoplastic Agents × Other hematologic neoplasm × Clear all
NCT00831766 2020-12-22

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
51 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡